anti-B7-H3 checkpoint inhibitor (Eberhard Karls University of Tubingen)

N/A

Report date: 2025/06/11 10:38:47

Base Information

Drug Nameanti-B7-H3 checkpoint inhibitor (Eberhard Karls University of Tubingen)
Drug Alias Name8H8-SDIE
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionT lymphocytes stimulantsCD276 antigen inhibitorsImmunostimulants
TargetsCD276 antigen
Therapy Area/IndicationsOvarian NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEberhard Karls University Tübingen
China Registration ClassN/A

Develop Information

Active CompaniesEberhard Karls University Tübingen
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A